GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioject Medical Technologies Inc (OTCPK:BJCT) » Definitions » Owner Earnings per Share (TTM)

Bioject Medical Technologies (Bioject Medical Technologies) Owner Earnings per Share (TTM) : 0.00 (As of Sep. 2011)


View and export this data going back to . Start your Free Trial

What is Bioject Medical Technologies Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bioject Medical Technologies's Owner Earnings per Share (TTM) ended in Sep. 2011 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Bioject Medical Technologies's Owner Earnings per Share (TTM) or its related term are showing as below:



BJCT's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 34.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Bioject Medical Technologies's Earnings per Share (Diluted) for the three months ended in Sep. 2011 was $0.01. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2011 was $0.01. It's PE Ratio ratio for today is 0.02.

Bioject Medical Technologies's EPS without NRI for the three months ended in Sep. 2011 was $0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2011 was $0.01. It's PE Ratio without NRI ratio for today is 0.02.


Bioject Medical Technologies Owner Earnings per Share (TTM) Historical Data

The historical data trend for Bioject Medical Technologies's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioject Medical Technologies Owner Earnings per Share (TTM) Chart

Bioject Medical Technologies Annual Data
Trend Mar01 Mar02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioject Medical Technologies Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bioject Medical Technologies's Owner Earnings per Share (TTM)

For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioject Medical Technologies's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bioject Medical Technologies's Price-to-Owner-Earnings falls into.



Bioject Medical Technologies Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Bioject Medical Technologies's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 0.47
Depreciation, Depletion and Amortization 0.47
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.04
Change In Working Capital -0.14
Shares Outstanding (Diluted Average) 38.20

1. Start with "Net Income" from income statement. Bioject Medical Technologies's Net Income for the trailing twelve months (TTM) ended in Sep. 2011 was $0.47 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Bioject Medical Technologies's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2011 was $0.47 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Bioject Medical Technologies's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2011 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.04 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Bioject Medical Technologies's 5-Year Average Maintenance Capital Expenditure = $0.04 Mil

5. "Change In Working Capital" is from cashflow statement. Bioject Medical Technologies's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2011 was $-0.14 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Bioject Medical Technologies's Shares Outstanding (Diluted Average) for the months ended in Sep. 2011 was 38.196 Mil.

Bioject Medical Technologies's Onwer Earnings Per Share for Sep. 2011 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 0.473 +0.467+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.041333333333333+-0.138)/38.196
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.0001/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Bioject Medical Technologies Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Bioject Medical Technologies's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioject Medical Technologies (Bioject Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Executives
James C Gale director 152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019
Sanders Morris Harris Inc/fa 10 percent owner, other: See General Remarks 600 TRAVIS, SUITE 5900, HOUSTON TX 77002
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Edward L Flynn director, 10 percent owner 211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Lof Partners Llc other: See general remarks 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Life Sciences Opportunities Fund Instittutional Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
J Michael Redmond officer: Sr. VP Bus Dev. 10 CANTERBURY ROAD, WINDHAM NH 03087
Elan Corp Plc 10 percent owner TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000
Elan International Services Ltd 10 percent owner C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2
Elan Pharmaceutical Investments Ltd 10 percent owner 102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999
John P Gandolfo officer: CFO 62 TERRACE ROAD, WAYNE NJ 07470
Grace K Fey director 1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2

Bioject Medical Technologies (Bioject Medical Technologies) Headlines

No Headlines